Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors (2012)
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 6 of these applications claim priority to application PCT/US2010/041538, filed Jul 9, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,682,979 | Substituted Pyrazolo [1,5-a] Pyrimidine Compounds as TRK Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence | ||
| US 9,782,415 | Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence | ||
| US 9,796,724 | Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence | ||
| US 10,251,889 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS In force · Medium confidence | Array Biopharma Inc. | In force | Medium confidence | ||
| US 10,758,542 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS TRK KINASE INHIBITORS In force · High confidence | Array Biopharma, Inc. | In force | High confidence | ||
| US 8,791,123 | Substituted Pyrazolo[1,5-a]pyrimidine Compounds as TRK Kinase Inhibitors In force · High confidence | Array Biopharma, Inc. | In force | High confidence |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.